Drug updated on 9/4/2024
Dosage Form | Tablet (oral; linagliptin/ metformin; 2.5 mg /500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg) |
Drug Class | Dipeptidyl peptidase-4 inhibitors and biguanides |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Latest News
Summary
- Jentadueto (linagliptin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- This summary is based on the review of one randomized controlled trial(s). [1]
- The probability of achieving normoglycemia was higher in the Linagliptin and Metformin (LM) group compared to the Metformin (M) group (OR 3.26, 95% CI: 1.55-6.84).
- The incidence of Type 2 Diabetes (T2D) was lower in the LM group compared to the M group (HR 4.0, 95% CI: 1.24-13.04, p = 0.020).
- The OGTT disposition index (DI), indicating pancreatic β-cell function, improved more significantly in the LM group across 6 and 24 months compared to the M group (p < 0.05).
- No major side effects were observed during the study, and no significant safety concerns or adverse effects were highlighted in the general population of prediabetic patients with impaired glucose tolerance and additional T2D risk factors.
- The study population consisted of prediabetic patients with impaired glucose tolerance and at least two additional T2D risk factors; in this subgroup, the Linagliptin and Metformin (LM) combination was more effective than Metformin alone in improving glucose metabolism, pancreatic β-cell function, and reducing T2D incidence.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Jentadueto (linagliptin and metformin hydrochloride) Prescribing Information. | 2023 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial. | 144Subjects F: 61% M: 39% | 2020 | Metabolism |
Sex Distribution:
F:61%
M:39%
144Subjects
Year:
2020
Source:Metabolism
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Management of individuals with diabetes at high risk for hypoglycemia: an endocrine society clinical practice guideline. | 2023 | The Journal of Clinical Endocrinology and Metabolism |
American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. | 2022 | AACE Endocrine Practice |
Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. | 2020 | Canadian Journal of Diabetes |